Clinical Trial

Hemodialysis-Induced Renal Perfusion Decline: Unraveling the Pathophysiological Mechanisms Linking Intradialytic Circulatory Stress to Residual Renal Function Loss

Study acronym: HD-RPD
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Residual renal function (RRF) plays a critical role in quality of life and survival in hemodialysis (HD) patients but characteristically declines after the initiation of HD. Owing to incomplete understanding of the pathophysiology underlying RRF decline, protective strategies remain limited. The aim of this study was to characterize the changes in renal perfusion in incident HD patients with preserved RRF during dialysis sessions and to provide new strategies for RRF preservation.
Trial Details
NCT Number NCT07003828
Lead Sponsor Yuanjun Yang
Conditions End-Stage Renal Disease Requiring Haemodialysis
Enrollment 30 participants
Start Date 2024-05-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-04